Olfactory neuroblastoma. A clinical analysis of 31 cases

Mariko Sekimizu; Wataru Shimbashi; Kazuyoshi Kawabata; Hiroki Mitani; Hiroyuki Yonekawa; Hirofumi Fukushima; Tohru Sasaki; Akira Seto; Mutsukazu Kitano; Yu Koizumi; Ryosuke Kamiyama; Aya Ebina; Mitsutaka Adachi; Yukiko Sato; Shunji Takahashi

doi:10.5981/jjhnc.43.8

Olfactory neuroblastoma. A clinical analysis of 31 cases

Mariko Sekimizu, Wataru Shimbashi, Kazuyoshi Kawabata, Hiroki Mitani, Hiroyuki Yonekawa, Hirofumi Fukushima, Tohru Sasaki, Akira Seto, Mutsukazu Kitano, Yu Koizumi, Ryosuke Kamiyama, Aya Ebina, Mitsutaka Adachi, Yukiko Sato, Shunji Takahashi

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Olfactory neuroblastoma (ONB) is a rare nasal malignancy. Because of its rarity, established treatments are lacking. The present retrospective study investigated the efficacy of CADO-CVP against ONB in 31 patients initially treated in the Department of Head and Neck at the Cancer Institute Hospital between 1992 and 2012. We have previously administered CADO-CVP as induction chemotherapy, achieving a high response rate. Fiveyear overall and disease-free survival rates were 82% and 53%, respectively. Disease-free survival rates differed significantly between the groups with and without induction chemotherapy. Four patients showed recurrence at over 5 years after initial treatment. We therefore consider that long-term follow-up is important for patients with ONB.

Original language	English
Pages (from-to)	8-12
Number of pages	5
Journal	Japanese Journal of Head and Neck Cancer
Volume	43
Issue number	1
DOIs	https://doi.org/10.5981/jjhnc.43.8
Publication status	Published - 2017
Externally published	Yes

Keywords

CADO-CVP
Induction chemotherapy
Olfactory neuroblastoma

ASJC Scopus subject areas

Otorhinolaryngology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.5981/jjhnc.43.8

Cite this

@article{90e07f02901e45e6bc72b7bcc78afcc9,

title = "Olfactory neuroblastoma. A clinical analysis of 31 cases",

abstract = "Olfactory neuroblastoma (ONB) is a rare nasal malignancy. Because of its rarity, established treatments are lacking. The present retrospective study investigated the efficacy of CADO-CVP against ONB in 31 patients initially treated in the Department of Head and Neck at the Cancer Institute Hospital between 1992 and 2012. We have previously administered CADO-CVP as induction chemotherapy, achieving a high response rate. Fiveyear overall and disease-free survival rates were 82% and 53%, respectively. Disease-free survival rates differed significantly between the groups with and without induction chemotherapy. Four patients showed recurrence at over 5 years after initial treatment. We therefore consider that long-term follow-up is important for patients with ONB.",

keywords = "CADO-CVP, Induction chemotherapy, Olfactory neuroblastoma",

author = "Mariko Sekimizu and Wataru Shimbashi and Kazuyoshi Kawabata and Hiroki Mitani and Hiroyuki Yonekawa and Hirofumi Fukushima and Tohru Sasaki and Akira Seto and Mutsukazu Kitano and Yu Koizumi and Ryosuke Kamiyama and Aya Ebina and Mitsutaka Adachi and Yukiko Sato and Shunji Takahashi",

year = "2017",

doi = "10.5981/jjhnc.43.8",

language = "English",

volume = "43",

pages = "8--12",

journal = "Japanese Journal of Head and Neck Cancer",

issn = "1349-5747",

publisher = "Nihon Tokeibu Gan Gakkai",

number = "1",

}

TY - JOUR

T1 - Olfactory neuroblastoma. A clinical analysis of 31 cases

AU - Sekimizu, Mariko

AU - Shimbashi, Wataru

AU - Kawabata, Kazuyoshi

AU - Mitani, Hiroki

AU - Yonekawa, Hiroyuki

AU - Fukushima, Hirofumi

AU - Sasaki, Tohru

AU - Seto, Akira

AU - Kitano, Mutsukazu

AU - Koizumi, Yu

AU - Kamiyama, Ryosuke

AU - Ebina, Aya

AU - Adachi, Mitsutaka

AU - Sato, Yukiko

AU - Takahashi, Shunji

PY - 2017

Y1 - 2017

N2 - Olfactory neuroblastoma (ONB) is a rare nasal malignancy. Because of its rarity, established treatments are lacking. The present retrospective study investigated the efficacy of CADO-CVP against ONB in 31 patients initially treated in the Department of Head and Neck at the Cancer Institute Hospital between 1992 and 2012. We have previously administered CADO-CVP as induction chemotherapy, achieving a high response rate. Fiveyear overall and disease-free survival rates were 82% and 53%, respectively. Disease-free survival rates differed significantly between the groups with and without induction chemotherapy. Four patients showed recurrence at over 5 years after initial treatment. We therefore consider that long-term follow-up is important for patients with ONB.

AB - Olfactory neuroblastoma (ONB) is a rare nasal malignancy. Because of its rarity, established treatments are lacking. The present retrospective study investigated the efficacy of CADO-CVP against ONB in 31 patients initially treated in the Department of Head and Neck at the Cancer Institute Hospital between 1992 and 2012. We have previously administered CADO-CVP as induction chemotherapy, achieving a high response rate. Fiveyear overall and disease-free survival rates were 82% and 53%, respectively. Disease-free survival rates differed significantly between the groups with and without induction chemotherapy. Four patients showed recurrence at over 5 years after initial treatment. We therefore consider that long-term follow-up is important for patients with ONB.

KW - CADO-CVP

KW - Induction chemotherapy

KW - Olfactory neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=85020876928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020876928&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.43.8

DO - 10.5981/jjhnc.43.8

M3 - Article

AN - SCOPUS:85020876928

SN - 1349-5747

VL - 43

SP - 8

EP - 12

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

IS - 1

ER -

Olfactory neuroblastoma. A clinical analysis of 31 cases

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this